Assay development and screening
Selvita provides its clients with effective drug discovery support based on broad capabilities and deep expertise in small molecule drug discovery. The in vitro pharmacology support offering at Selvita covers drug discovery phases from target validation through to preclinical candidate selection. We provide a versatile protein-to-cell approach for the development of pharmacologically active compounds and biologics.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Selvita’s in vitro pharmacology branch combines several approaches supporting drug discovery process, including custom assay development and screening/profiling services up to 1536-well plate format. Our platforms execute a number of ready-to-use or readily adaptable assays that cover many areas of interest, as well as challenging assays developed on-demand. Multiple readouts are available from classical absorbance, fluorescence and luminescence through fluorescence and bioluminescence energy transfer (TR-FRET, BRET) or Alpha technology. Using cell-based assays, we perform small molecule or biologics activity analysis employing internal repository of cells. The assays are highly automated and analyzed in high throughput, yielding results with high statistical power. Moreover, bias-free analytical pipelines allow for analysis of large datasets resulting from screening of large compound libraries. HTS is one of the first phases of the drug discovery, performed just after the conception of the idea of new drug development. We employ a fully automated HTS platform (platform is based on Beckman Coulter Access Workstation) allowing testing of at least 10,000 assay points a day across a wide range of biochemical and cellular assay types. as well as set of diverse and focused compounds libraries, including fragments, macrocycles and natural products. The great added value to Selvita’s HTS is AI-based iterative approach including machine learning algorithms, highly extending screening capabilities.
We operate High Content Screening (HCS) approach in support of client projects, in our new state-of-the-art HCS laboratory equipped with advanced Leica inverted fluorescent microscope and Perkin Elmer Operetta CLS. All activities are furthermore supported by additional modern equipment to provide fully-integrated drug discovery programs. The ability to combine multiple readouts in a single assay reduces the cost and provides vast amount of data to reach decisions during drug discovery cycles. Usually, multi-factor design of experiments is employed during method development. It accelerates optimization of the assay performance, thus helping to obtain a measurement system that meets its requirements. Images generated by the HCS system are analyzed by human-defined or AI-based algorithms, further boosting high content approach.
At Selvita we additionally provide support for drug discovery programs using the range of biophysical methods which allow us to conduct screening of low-to-medium size libraries in hit identification stage, perform binding studies of selected drug candidates to their targets and support standard quality control in protein production. Biophysical platform includes Surface Plasmon Resonance (SPR), Temperature Related Intensity Change (TRIC), Fluorescence Thermal Shift Assay/Differential Scanning Fluorimetry, Isothermal Titration Calorimetry (ITC), Fluorescence Polarization (FP) and Radioligand Binding Assay (RBA). Thanks to such specific technologies, we support analysis of drug binding to target protein, greatly extending interactions studies for further drug discovery and development purposes.
We constantly develop our equipment and assays to meet the requirements of our customers. With a set of Selvita’s in vitro pharmacology platforms and efforts of our highly skilled scientists, we support drug discovery programs in the drug discovery pipeline bringing our customers closer to the final drug product.
Key features:
Expertise in variety of therapeutics areas, including oncology, immuno-oncology, neuroscience, inflammation, fibrosis.
Short DMTA cycle and reporting lead time.
Responsiveness and flexibility to customer requests.
Automation and AI-based approaches accelerating drug discovery process.
Structure-based, Image-based and Frament-based drug discovery.
Relevant applications for the product:
In vitro pharmacology support across target validation, HitID, H2L, LO and pre-clinical candidate stages of drug discovery pipeline.
Screening of compound libraries employing biochemical, biophysical and cell-based approach (HitID).
Binding studies within Selvita’s biophysical platform.
Enzymatic assays to support target activity studies, including HTS.
Cell-based phenotypic assays, including HCS.
